Multifactorial impact on the outcome of interval debulking surgery in patients with advanced epithelial ovarian or peritoneal cancers

Clin Chim Acta. 2019 Aug:495:148-153. doi: 10.1016/j.cca.2019.03.1613. Epub 2019 Mar 15.

Abstract

Objective: To evaluate the impact of multiple clinical features upon the outcome of interval cytoreductive surgery and thus upon the survival in patients with advanced ovarian cancer and primary peritoneal carcinoma.

Methods: A retrospective analysis of patients receiving NACT followed by IDS between 2009 and 2017. Patients were analyzed according to the pre-NACT CA125, pre-IDS CA125, pre-IDS CA125 decline, patients' pre-IDS BMI, multisite bowel involvement and different working years of surgeons, for their influence upon the IDS outcome (e.g. optimal vs suboptimal) and the survival.

Results: After interval debulking surgery following 1-6 cycles of NACT, all patients analyzed were identified as optimal (n = 113) and suboptimal (n = 47) based on patients' record. The PFS/OS were 21/68 months and 9/26 months in optimal and suboptimal groups, respectively (p = .000, p = .000). Although differential levels of pre-IDS CA125, pre-IDS CA125 decline, bowel involvement and surgeons' working years were found to be significantly different between the two groups, surgeons' working years and multisite bowel invasion were the independent factors for IDS outcome, and the latter one was also highly related to survival.

Conclusions: Following NACT, the rate of optimal IDS might be improved for patients without multisite bowel involvement. For those with bowel involvement, management strategy made by well-experienced surgeons might be a key factor for the outcome of IDS.

Keywords: Cytoreductive surgery outcome; IDS; NACT; Ovarian cancer; Prognosis.

MeSH terms

  • Adult
  • Aged
  • CA-125 Antigen / blood
  • Carcinoma, Ovarian Epithelial* / blood
  • Carcinoma, Ovarian Epithelial* / pathology
  • Carcinoma, Ovarian Epithelial* / surgery
  • Cytoreduction Surgical Procedures*
  • Disease-Free Survival
  • Female
  • Humans
  • Middle Aged
  • Peritoneal Neoplasms* / blood
  • Peritoneal Neoplasms* / pathology
  • Peritoneal Neoplasms* / surgery
  • ROC Curve
  • Retrospective Studies
  • Treatment Outcome

Substances

  • CA-125 Antigen